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Results: Gemfibrozil unexpectedly reduced the peak plasma con-
centration (Cmax) of imatinib by 35% (P < 0.001). Gemfibrozil also 
reduced the Cmax and area under the plasma concentration–time curve 
(AUC0–∞) of N-DMI by 56% and 48% (P < 0.001), while the AUC0–∞ 
of imatinib was unaffected. Furthermore, gemfibrozil reduced the 
Cmax/C24 h ratios of imatinib and N-DMI by 44% and 17% (P < 
0.05), suggesting diminished daily fluctuation of imatinib plasma 
concentrations during concomitant use with gemfibrozil. PBPK simu-
lations suggested an increased contribution (70%) for CYP2C8 to the 
hepatic metabolic clearance of imatinib during long-term treatment 
with the most common imatinib dosing, 400 mg once daily. The 
impaired imatinib absorption observed during the gemfibrozil phase 
was best explained by inhibition of an intestinal influx transporter 
involved in imatinib absorption.
Conclusion: This study shows for the first time that CYP2C8 is 
important in the metabolism of imatinib in humans, and that an 
influx transporter may be relevant for imatinib absorption in vivo. 
Given that the efficacy and adverse effects of imatinib are dose-
dependent, care is warranted when gemfibrozil is used in combina-
tion with imatinib.
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Introduction: There are still controversies over pill substitution 
among AEDs: some studies claimed that switching between brand 
and generic AED (generic substitution) can lead to breakthrough 
seizures; other studies have refuted these concerns. France and some 
US states recommend limiting substitution of generic AED. We aimed 
at further estimating the association between generic substitution and 
loss of seizure control.
Patients (or Materials) and Methods: We used data from the French 
National Health Insurance Information System linked with the 
French Hospital Discharge Database to identify a cohort of patients 
aged 18 years or more who filled a prescription in 2010 for AED 
that had at least 1 brand-name and 1 generic form available on the 
French market (carbamazepine, lamotrigine, levetiracetam, oxcar-
bazepine, topiramate, or valproic acid). Patients with a medical his-
tory of stroke or cancer and women who gave birth (ICD-10 codes, 
O80–O84) were excluded. We used a case-crossover design to assess 
the relationship between seizure-related hospitalization and generic 
substitution. For this preliminary analysis, cases were identified as 
individuals with a seizure-related hospitalization between July 2010 
and December 2010 (ICD-10 codes, G40 or G41). The index date 
was defined as the date of first occurrence in the inpatient file of the 
codes of interest pending a preceding hospitalization-free period of at 
least 6 months with regular dispensations of targeted AED. The case 
period corresponded to the 3 months preceding the index date; the 
control period was defined as the 3 months immediately preceding the 
case period. Generic substitution was defined as a filled prescription 
for a generic AED that was preceded by a filled prescription for a 
brand-name counterpart. Matched odds ratio estimates were based 
on the ratio of discordant pairs of case and control periods in regard 
to generic substitution; ORs and 95% CIs were estimated using con-
ditional logistic regression model. All analyses were conducted using 
the SAS statistical package (version 9.2; SAS Institute).
Results: The cohort included 566,549 adult patients filling targeted 
AED. We identified 10,089 patients with eligible seizure-related hos-
pitalization in the second half of 2010, excluding stroke, cancer, and 
childbirth. Among them, 2980 had regular dispensations. Generic 
substitution was observed in 461 patients, 273 in the case period and 
258 in the control period; matched OR = 1.08 (95% CI, 0.88–1.32).
Conclusion: Generic substitution was not associated with an elevated 
risk of seizure-related hospitalization.
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Introduction: Studies have shown that the cloned enzyme donor 
immunoassays (CEDIA) for buprenorphine, methadone, and 2-eth-
ylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) might be suit-
able for drugs-of-abuse testing in urine, but sensitivity, specificity, 
and optimal cutoff are to be determined. The aim of this study was 
to evaluate the overall performance of CEDIA compared with liquid 
chromatography tandem mass spectrometry (LC-MS/MS) for analy-
sis of buprenorphine, methadone, and EDDP in urine.
Patients (or Materials) and Methods: All urine samples sent to the 
Laboratory of Clinical Biochemistry at the Haukeland University 
Hospital for drugs-of-abuse testing in a period of 4 weeks in 
November–December 2011 were consecutively analyzed with both 
CEDIA and LCMSMS. Samples were from heroin-addicted patients 
enrolled in medication-assisted rehabilitation (MAR), treated with 
either buprenorphine or methadone, and from patients who were not 
treated with these drugs (non-MAR).
Results: A total of 2272 urine samples were included in the study; 
996 urine samples (43% of all samples) were from patients enrolled 
in MAR. The CEDIA assay for methadone, EDDP, and buprenorphine 
had a sensitivity of 97.4%, 98.8%, and 100% and a specificity of 
100%, 100%, and 98.0%, respectively. All samples with false-negative 
results in the CEDIA EDDP assay had also false-negative results in the 
methadone assay. A change in the CEDIA buprenorphine assay cutoff 
from the manufacturer’s recommendation on 5 ng/mL to 10 ng/mL 
gave a better specificity, with a reduction from 32 to 5 false-positive 
results. Most of the false-positive results in the CEDIA buprenorphine 
assay could be explained by cross-reactivity with codeine and mor-
phine but in concentrations lower than previously reported.
Conclusion: The CEDIA assays for buprenorphine and EDDP are 
suitable as screening methods for drugs-of-abuse testing in urine. The 
methadone assay did not provide additional information to the EDDP 
assay and may be redundant. We propose a cutoff concentration 
of 10 ng/mL for the CEDIA buprenorphine assay. Cross-reactivity 
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in the CEDIA buprenorphine assay should be the object of further 
studies. For MAR patients, more specific methods than CEDIA are 
recommended to omit negative sanctions based on false-positive or 
false-negative results.
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Introduction: Self-empowering patients on oral anticoagulation may 
improve their safety and the outcome of this therapy. The aim of 
this study was to evaluate the effect of an individual, video-assisted, 
1-hour education on patient knowledge and on anticoagulation sta-
bility as an intermediate end point.
Patients (or Materials) and Methods: In a cluster-randomized trial 
in 22 general practices, we investigated 369 patients who were on 
oral anticoagulation with phenprocoumon. In 11 practices, trained 
practice nurses educated the patients individually based on a 20-min-
ute video, a leaflet, and a concluding questionnaire. The education 
lasted three quarters of an hour to an hour. Patients in the 11 control 
practices were handed over the leaflet and otherwise treated as usual. 
Patient knowledge was evaluated by questionnaires before and 6 
months after the education; anticoagulation stability was evaluated 
by the international normalized ratio (INR) in the 6-month periods 
before and after the intervention.
Results: Six months after the intervention, the educated patients had 
better safety-relevant knowledge and their anticoagulation tended to 
be more stable than before the education. Knowledge and INR stabil-
ity did not change in the controls. In particular, 68% of the patients 
knew that acetaminophen (paracetamol) is the safest over-the-counter 
analgesic for the combination with phenprocoumon compared with 
22% before (P < 0.001). Basic diet rules were known to 71% of the 
patients compared with 30% before (P < 0.001). Painful swelling 
realized 60% as a signal symptom compared with 26% before (P < 
0.001). Suddenly disturbed speech was a signal symptom to 80% 
compared with 49% of these patients before the education (P < 
0.001). How to proceed after a forgotten intake knew 57% compared 
with 14% before the education (P < 0.001). The INR was outside 
the intended range for 29% of the time during the 6 months after 
the education in the intervention group compared with 36% of the 
time in the control patients (P = 0.09).
Conclusion: Self-empowering patients with this 1-hour education 
significantly improved patient knowledge over 6 months and tended 
to improve the intermediate end point INR stability. This education 
could be easily implemented in routine practice. In addition, this 
education provides a promising example to self-empower patients 
in further therapies.
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Introduction: Acenocoumarol is a vitamin K antagonist charac-
terized by a large interpatient variability in the dose required to 
achieve target anticoagulation. There is extensive evidence that a 
large part of the variability of VKAs can be explained by genetic 
factors, especially polymorphisms in the VKORC1 and the CYP2C9 
genes. The objective of this study was to investigate the impact of 
CYP2C9 polymorphisms and drug−drug interactions on the risk of 
overanticoagulation and on the mean daily dose in patients treated 
with acenocoumarol.
Patients (or Materials) and Methods: This prospective observational 
study included 115 hospitalized patients starting acenocoumarol treat-
ment. Data were collected during the first 35 days of therapy and included 
sex, age, INR measurements, acenocoumarol doses, comorbidities, and 
comedications. Patients were genotyped for CYP2C9, CYP2C19, and 
VKORC1. Drugs known to inhibit CYP2C9 using the table developed 
by the Division of Clinical Pharmacology and Toxicology, Geneva 
University Hospitals, Switzerland, were carefully listed.
Results: The difference for time to overanticoagulation in pres-
ence or absence of CYP2C9 inhibitors for all patients, independ-
ent of the genotype, was significant (P < 0.001). The presence of 
a CYP2C9 inhibitor or a CYP2C9 polymorphism, independently, 
statistically increased the risk of overanticoagulation (HR = 2.8 [P < 
0.001] and HR = 1.7 [P = 0.004], respectively). For CYP2C9*1/*1 
genotype only, in the presence of a CYP2C9 inhibitor, 52% of 
wild-type patients presented an INR ≥ 4 versus 22% in absence of 
a CYP2C9 inhibitor. In wild-type patients, the HR was 2.7 (P = 
0.02) in the presence of a CYP2C9 inhibitor compared with the 
absence of CYP2C9 inhibitor. For patients carriers of CYP2C9*2 or 
CYP2C9*3 alleles, in the presence of a CYP2C9 inhibitor, 78% of 
carriers presented an INR ≥ 4 versus 48% in the absence of CYP2C9 
inhibitor. For patients carriers of CYP2C9*2 or CYP2C9*3 alleles, 
the HR was 2.9 (P = 0.01) in presence of a CYP2C9 inhibitor. 
Presence of the CYP2C9*3 allele and VKORC1-1639GA and 
VKORC1-1639AA were significantly associated with a lower dose 
compared with wild-type subjects with a decrease of nearly 35%, 
25%, and 45%, respectively, in dose requirement. CYP2C9*2 and 
CYP2C19*2 were not associated with lower acenocoumarol doses. 
The presence of a CYP2C9 inhibitor was associated with a decrease 
of 20% in dose requirement (P < 0.05).
Conclusion: The results of our study confirm that the presence of at 
least 1 allelic variant of CYP2C9 and/or the prescription of CYP2C9 
inhibitors expose patients to an increased additive risk of overanti-
coagulation. The VKORC1-1639GA and -1639AA genotypes and 
the presence of a CYP2C9*3 allele were associated with a lower dose 
of acenocoumarol. These findings support that CYP2C9 genotyping 
could be useful for identifying patients requiring a closer monitoring, 
especially in the presence of a CYP2C9 inhibitor.
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